AusBiotech to submit to Senate’s Australian innovation system inquiry

22 April 2014

Trade group AusBiotech is preparing a submission, following the Senate's referral of an inquiry into Australia's innovation system to the Senate Economics References Committee for inquiry and report.

A number of the Terms of Reference to the Inquiry align with recent AusBiotech advocacy; in particular the industry body has welcomed the Inquiry’s focus on translation of research into benefits for Australians, the relationship between advanced manufacturing and a healthy innovation system, and AusBiotech supports the creation of “a seamless innovation pipeline.”

Challenges posed by global competition

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology